ArticleJournal of cardiothoracic surgery2026
The CRP-albumin-lymphocyte (CALLY) index is an independent prognostic factor for patients undergoing transcatheter aortic valve implantation.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe C-reactive protein-albumin-lymphocyte (CALLY) index is an emerging composite biomarker that integrates inflammatory, nutritional, and immune parameters. Although its prognostic utility has been established in oncological and certain cardiovascular contexts, its role in predicting outcomes following transcatheter aortic valve implantation (TAVI) remains unclear. This study aimed to investigate the prognostic value of the CALLY index in patients with severe aortic stenosis undergoing TAVI, with a focus on its association with all-cause mortality.
methodsA single-center, retrospective cohort study was conducted including 330 patients who underwent TAVI for severe aortic stenosis between December 2016 and January 2025. The CALLY index was calculated using preprocedural C-reactive protein, serum albumin, and lymphocyte count. Primary outcome was the incidence of all-cause mortality.
resultsThe CALLY index was lower in deceased patients than in survivors (1.0 [0.4-2.0] vs. 3.0 [1.0-10.6], p < 0.001). In multivariable analysis, a lower CALLY index was independently associated with higher all-cause mortality (HR: 0.965, 95% CI: 0.933-0.997, p = 0.034). The optimal cut-off value of the CALLY index for predicting all-cause mortality was 2.21, with an AUC of 0.730 (95% CI: 0.674-0.787), sensitivity of 76.7%, and specificity of 61.3% (p < 0.001).
conclusionsThe CALLY index was independently associated with all-cause mortality in patients with severe aortic stenosis undergoing TAVI. As a simple and readily available biomarker, it may help support early risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.